With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust ...

Temperature is a key physiological factor that determines the speed of immune reactions. While this may seem obvious, it has ...

"This process appears to be regulated by myosin-binding protein-C (cMyBP-C), which is a heart muscle protein," study author Kerry McDonald said. "Our study investigated its role in cardiac muscle ...

Braveheart Bio, a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions, today announced its launch with $185 million in ...

Myosin-V processively walks on actin filaments in a hand-over-hand fashion. The identical structures of the heads predict a symmetric hand-over-hand mechanism where regular, unidirectional rotation ...

The novel cardiac myosin inhibitor aficamten improved peak oxygen uptake in symptomatic obstructive hypertrophic cardiomyopathy (HCM), the pivotal SEQUOIA-HCM trial showed. At 24 weeks, the mean ...

Using technologies like electron microscopy (EM) it is possible to capture molecular mechanisms in great detail, but not when these mechanisms are currently moving. The field of cryomicroscopy ...

A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new ...

Interested parties may access the live webcasts of the fireside chats by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replays will be ...

GAINESVILLE, Fla. (WCJB) - In this week’s Tech Tuesday, our partners at UF Innovate and SCAD Media highlight Myosin ...

Each year, about 14,000 people in the United States are diagnosed with glioblastoma, one of the deadliest primary brain tumors. With standard treatments of surgery, radiation, and chemotherapy ...